Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Rebound Pain in Knee Arthroplasty
NCT06555458Completed
- Sponsor
- Ankara City Hospital
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine (2 arms), sponsored by Ankara City Hospital. Primary endpoint: Rebound pain VAS scores and incidence of rebound pain at 48 hours. Started Nov 2023; status: completed.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on NCT06555458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555458.